AmyLeeLightnerMD

Colon & Rectal Surgery • La Jolla, CA

Physician

Join to view full profile

Dr. Lightner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lightner's full profile

Already have an account?

Office
10710 N Torrey Pines Rd
La Jolla, CA 92037
Phone+1 858-554-8984

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Surgery, 2008 - 2015
Mayo Clinic College of Medicine and Science (Rochester)Residency, Colon and Rectal Surgery, 2008 - 2009
Boston University School of MedicineClass of 2008

Certifications & Licensure

CA State Medical License 2023 - 2025
OH State Medical License 2016 - 2024
MN State Medical License 2015 - 2019
American Board of Colon and Rectal Surgery Colon & Rectal Surgery
American Board of Surgery Surgery

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons

Clinical Trials

Stem Cell Coated Fistula Plug in Patients With Crohn's RVF Start of enrollment: 2017 Oct 19
Completed
Phase 1
Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's Start of enrollment: 2021 Jun 01
Withdrawn
Phase 1
Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease Start of enrollment: 2020 Nov 19
Recruiting
Phase 1, Phase 2
Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease Start of enrollment: 2020 Oct 28
Recruiting
Phase 1, Phase 2
Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease Start of enrollment: 2020 Oct 28
Recruiting
Phase 1, Phase 2
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) Start of enrollment: 2020 Nov 10
Recruiting
Phase 1, Phase 2
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis Start of enrollment: 2020 Nov 04
Recruiting
Phase 1, Phase 2
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES) Start of enrollment: 2020 Jul 28
Recruiting
Not Applicable
Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease Start of enrollment: 2021 Apr 01
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

11 citations
A phase IB/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: a...
Amy L Lightner, Neda Dadgar, Caroline Matyas, Kavita Elliott, Clifton Fulmer
Colorectal Disease. 2022-11-01
1 citations
Redo Ileocolic Resection Is Not an Independent Risk Factor for Anastomotic Leak in Recurrent Crohn's Disease.
Songsoo Yang, Christopher Prien, Xue Jia, Tracy Hull, David Liska
Diseases of the Colon and Rectum. 2023-10-01
20 citations
Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn’s Disease Patients Undergoing Ileocolic Resection
Ravi S. Shah, Salam P. Bachour, Xue Jia, Stefan D. Holubar, Tracy L. Hull
Journal of Crohn's & Colitis. 2021-07-05

Press Mentions

CORRECTING and REPLACING Direct Biologics Reports Compelling Data as ExoFlo™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 SubjectsApril 19th, 2023
Direct Biologics Reports Compelling Data as ExoFlo™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 SubjectsApril 19th, 2023
Direct Biologics Reports Compelling Results from Phase 2 Trial with ExoFlo™ in Hospitalized Patients with Respiratory Failure or Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19March 14th, 2023
Join now to see all

Professional Memberships

American College of Surgeons - ACS
Member